Sonic Healthcare Limited (SKHCF)
| Market Cap | 6.74B -14.6% |
| Revenue (ttm) | 6.95B +11.7% |
| Net Income | 359.79M -1.1% |
| EPS | 0.74 -2.7% |
| Shares Out | n/a |
| PE Ratio | 18.75 |
| Forward PE | 14.70 |
| Dividend | 0.73 (5.08%) |
| Ex-Dividend Date | Mar 4, 2026 |
| Volume | 500 |
| Average Volume | 4,725 |
| Open | 13.09 |
| Previous Close | 14.30 |
| Day's Range | 13.09 - 13.71 |
| 52-Week Range | 12.70 - 19.34 |
| Beta | 0.57 |
| RSI | 46.57 |
| Earnings Date | May 19, 2026 |
About Sonic Healthcare
Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, ... [Read more]
Financial Performance
In fiscal year 2025, Sonic Healthcare's revenue was 9.65 billion, an increase of 7.56% compared to the previous year's 8.97 billion. Earnings were 513.60 million, an increase of 0.49%.
Financial numbers in AUD Financial StatementsNews
Sonic Healthcare Earnings Call Transcript: H1 2026
Revenue grew 5% organically in H1 FY2026, with strong results in Australia, Germany, and the UK. EBITDA margin improved, guidance was reaffirmed, and capital management initiatives—including property sales and potential buybacks—are underway.
Sonic Healthcare Transcript: AGM 2025
The meeting marked a major leadership transition, reviewed solid financial results, and reaffirmed a focus on medical leadership, sustainability, and disciplined growth. Shareholders approved all resolutions and received updates on acquisitions, dividends, and ongoing strategic priorities.
Sonic Healthcare Earnings Call Transcript: H2 2025
Revenue and EBITDA both grew 8% year-over-year, with strong cash generation and margin expansion. FY 2026 guidance anticipates up to 19% EPS growth, driven by organic growth and recent acquisitions, while integration and synergy capture are underway across key geographies.
Sonic Healthcare initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Davin Thillainathan initiated coverage of Sonic Healthcare (SKHHY) with a Buy rating and A$32.20 price target While funding reforms in Germany are a headwind to the company’s
Sonic Healthcare initiated with an Equal Weight at Morgan Stanley
Morgan Stanley initiated coverage of Sonic Healthcare (SKHHY) with an Equal Weight rating and A$28.10 price target Modest EPS growth has been impacted by declining margins and the company’s return
Sonic Healthcare Earnings Call Transcript: H1 2025
Strong half-year results with 8% revenue and 17% net profit growth, driven by organic expansion, cost control, and recent acquisitions. Margin expansion and robust cash flow support positive guidance, with major synergies expected from the Kramer Group acquisition and ongoing operational improvements.
M&A News: Sonic Healthcare Boosts German Presence with LADR Acquisition
ASX-listed Sonic Healthcare Limited ($AU:SHL) has announced the acquisition of Germany-based laboratory group LADR for an enterprise value of €423 million, bolstering its presence in the German health...
Sonic Healthcare Shares Gain on Upbeat Outlook
Shares of ASX-listed Sonic Healthcare Limited ($AU:SHL) gained 7% as of writing after the company shared an upbeat outlook for its revenue growth in an investor update at its 2024
Sonic Healthcare Transcript: AGM 2024
The meeting highlighted strong base business growth, ongoing integration of major acquisitions, and a continued focus on digital and AI-driven transformation. All resolutions passed, with board renewal and cost management initiatives set to drive future margin and earnings improvements.
Sonic Healthcare Earnings Call Transcript: H2 2024
FY 2024 saw strong organic growth, major acquisitions, and a return to margin expansion, with EBITDA of AUD 1.602 billion and a 2% dividend increase. Guidance for FY 2025 targets up to 10% EBITDA growth, supported by easing inflation and integration of recent acquisitions.
Sonic Healthcare Earnings Call Transcript: H1 2024
Sonic Healthcare Transcript: AGM 2023
Sonic Healthcare Earnings Call Transcript: H2 2023
Sonic Healthcare upgraded to Buy from Neutral at Citi
Citi analyst Mathieu Chevrier upgraded Sonic Healthcare to Buy from Neutral with a price target of A$36, up from A$34.50. The analyst believes the company’s earnings risk is to the